Alkermes Plc (ALKS)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 655,427 | 239,200 | 365,549 | 275,854 | 322,853 |
Revenue | US$ in thousands | 1,639,870 | 1,099,460 | 1,162,060 | 1,032,500 | 1,156,450 |
Gross profit margin | 39.97% | 21.76% | 31.46% | 26.72% | 27.92% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $655,427K ÷ $1,639,870K
= 39.97%
The gross profit margin of Alkermes plc has shown fluctuations over the past five years, ranging from 80.38% in 2022 to 84.79% in 2023. Despite these variations, the company has maintained a relatively high level of gross profit margin, indicating strong profitability in its core operations. The margins for 2021, 2020, and 2019 were 83.18%, 82.83%, and 84.59%, respectively. Overall, Alkermes plc has demonstrated a consistent ability to generate value from its production activities, although some fluctuations in the margin suggest changes in cost structures or pricing strategies.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Alkermes Plc
ALKS
39.97%
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
16.39%
Amphastar P
AMPH
54.49%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
-6.84%
Biomarin Pharmaceutical Inc
BMRN
78.31%
Bristol-Myers Squibb Company
BMY
37.71%
Catalent Inc
CTLT
21.75%
Catalyst Pharmaceuticals Inc
CPRX
45.19%
Collegium Pharmaceutical Inc
COLL
70.92%